

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8


Clone #13 (no PXR)

FIG. 9




FIG. 10




FIG. 11

Effect of Serum, DMSO, and Rifampicin on Luciferase Activity





FIG. 12

Human Hepatocytes # 899
10 µg RNA per well



- Lane 1, DMSO with 0.1 µM DEX
- Lane 2, DMSO no DEX
- Lane 3, 10 µM DEX
- Lane 4, 1 mM Phenobarbital
- Lane 5, 10 µM Rifampicin
- Lane 6, 10 µM Clotrimazole
- Lane 7, 10 µM RU486

1 2 3 4 5 6 7

FIG. 13

hPXR-3A4 colony 1F




FIG. 14

3A4 Colony 13




FIG. 15

Colony 13 Drug Screen




FIG. 16




FIG. 17






FIG. 18

B**A****FIG. 19**




FIG. 20




FIG. 21

FIG. 22

25/48





FIG. 23






FIG. 25A




FIG. 25B





FIG. 26A

DRE12-6








FIG. 27








FIG. 28B

1. 3.1 ug/ml grapeseed extract
2. 31 ug/ml grapeseed extract
3. 10 ug/ml garlic
4. 100 ug/ml garlic
5. 10 ug kava-kava
6. 100 ug kava-kava
7. 10 ug/ml ginseng
8. 100 ug/ml ginseng
9. DMSO

FIG. 29




FIG. 30A




FIG. 30B
DPX-2




FIG. 30C
DPX-2






FIG. 31

1 2 3 4 5 6 7 8



1. LS174T, RIF 10
2. LS174T, RIF 2.5
3. LS174T, RIF 0.5
4. LS174T, omp 100
5. LS174T, Mif 10
6. LS174T, Dex 100
7. LS174T, PCN 10
8. LS174T, DMSO



1. Hepatocyte, DMSO
2. Hepatocyte, Rif
3. LS174T, DMSO
4. LS174T, Rif 10

FIG. 32B

1 2 3 4

MDR1




CYP3A4



FIG. 32C

40/48

18s rRNA



- | | |
|---------------------|---------------------|
| 1.HepG2, DMSO | 1. Caco-2, DMOS |
| 2.HepG2, RIF 10 | 2. Caco-2, RIF 10 |
| 3.HepG2,hPXR DMSO | 3. Caco-PXR, DMOS |
| 4.HepG2,hPXR RIF 10 | 4. Caco-PXR, RIF 10 |

FIG. 33A
RT-PCR for PXR Expression




FIG. 33B




FIG. 34A
Caco-2

43/48




FIG. 34B
HepG2




FIG. 35A

Hep-PXR/Pgp-Luc




FIG. 35B
CaCO-PXR/PgPLuc ■ 48 H treatment




FIG. 36
HepG/Pgp-Luc

